Orlistat and weight loss support for uric acid control in gout with obesity
Tests orlistat plus weight loss support in adults with gout and obesity.
Plain-language title generated from the registry record
Registry title: Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT
Key facts
- Where
- Shenyang, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07326839, who can take part
Where in China
- General Hospital of Northern Theater Command, PLAShenyang, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- XueMei Guo
- Trial code
- NCT07326839
- Record updated
- 8 January 2026
- Original description
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels <360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.Read full original descriptionShow less
Optimization of Blood Uric Acid Control in Obese Gout Patients by Orlistat-Mediated Metabolic Remodeling and Intensive Weight Management: A Randomized Controlled Trial
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels <360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.
Inclusion: Meeting the 2015 ACR/EULAR classification criteria for gout; Age 18-70 years; BMI ≥28 kg/m²; Serum uric acid ≥480 μmol/L; Willing and able to comply with the study protocol.
Exclusion: Contraindications to orlistat or other gout medications; History of severe allergy or adverse reactions to study drugs; Malignancy; Severe hepatic or renal dysfunction; Pregnant or lactating women; Secondary gout; Poor compliance or inability to cooperate; Participation in other clinical trials within the last 3 months.